SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022.

COVID-19 Chicago HIV/AIDS Illinois PWH PWOH SARS-CoV-2 United States public health surveillance reinfection respiratory infections severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
11 2023
Historique:
medline: 26 10 2023
pubmed: 25 10 2023
entrez: 25 10 2023
Statut: ppublish

Résumé

Understanding if persons with HIV (PWH) have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance. To determine whether HIV infection was associated with increased risk for SARS-CoV-2 reinfection, we followed adult residents of Chicago, Illinois, USA, with SARS-CoV-2 longitudinally from their first reported infection through May 31, 2022. We matched SARS-CoV-2 laboratory data and COVID-19 vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System. Among 453,587 Chicago residents with SARS-CoV-2, a total of 5% experienced a SARS-CoV-2 reinfection, including 192/2,886 (7%) PWH and 23,642/450,701 (5%) persons without HIV. We observed higher SARS-CoV-2 reinfection incidence rates among PWH (66 [95% CI 57-77] cases/1,000 person-years) than PWOH (50 [95% CI 49-51] cases/1,000 person-years). PWH had a higher adjusted rate of SARS-CoV-2 reinfection (1.46, 95% CI 1.27-1.68) than those without HIV. PWH should follow the recommended COVID-19 vaccine schedule, including booster doses.

Identifiants

pubmed: 37877555
doi: 10.3201/eid2911.230577
pmc: PMC10617359
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2257-2265

Références

Cell Mol Immunol. 2021 Jul;18(7):1832-1834
pubmed: 34099890
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):118-124
pubmed: 35085218
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
J Infect. 2021 Aug;83(2):237-279
pubmed: 34052241
Clin Infect Dis. 2021 Jun 15;72(12):e1021-e1029
pubmed: 33252620
Emerg Infect Dis. 2022 Aug;28(8):1729-1731
pubmed: 35738346
Clin Infect Dis. 2021 Nov 16;73(10):1882-1886
pubmed: 33718968
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Clin Microbiol Infect. 2021 Dec;27(12):1860.e7-1860.e10
pubmed: 34419576
MMWR Morb Mortal Wkly Rep. 2022 Jan 07;71(1):19-25
pubmed: 34990440
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):549-555
pubmed: 35421077
J Med Virol. 2021 Jan;93(1):506-512
pubmed: 32644223
JAMA Netw Open. 2022 Jun 1;5(6):e2215934
pubmed: 35671054
MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10
pubmed: 24717910
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33361342
JMIR Public Health Surveill. 2022 May 24;8(5):e35311
pubmed: 35486806
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083
pubmed: 34383732
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
MMWR Morb Mortal Wkly Rep. 2022 Apr 08;71(14):524-526
pubmed: 35389976
JAMA Intern Med. 2022 Feb 1;182(2):153-162
pubmed: 34962505
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Eur J Clin Invest. 2022 Oct;52(10):e13845
pubmed: 35904405
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
J Investig Med. 2021 Aug;69(6):1253-1255
pubmed: 34006572
AIDS Care. 2013;25(4):451-8
pubmed: 22894702
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1539-1544
pubmed: 34735425
Clin Infect Dis. 2022 Apr 28;74(8):1489-1492
pubmed: 34351392
Clin Case Rep. 2021 Jan 13;9(3):1397-1401
pubmed: 33768853
J Public Health Manag Pract. 2014 Sep-Oct;20(5):506-12
pubmed: 24335712
Prev Chronic Dis. 2021 Jul 01;18:E66
pubmed: 34197283
Am J Transplant. 2021 Aug;21(8):2916-2918
pubmed: 34101990
Clin Infect Dis. 2022 Aug 24;75(1):e662-e671
pubmed: 35028662
Lancet Infect Dis. 2022 Jun;22(6):781-790
pubmed: 35366962
Clin Infect Dis. 2014 Dec 15;59(12):1787-97
pubmed: 25182245

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH